Intellia Therapeutics (NTLA) Common Equity (2016 - 2025)
Historic Common Equity for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $748.4 million.
- Intellia Therapeutics' Common Equity fell 2225.12% to $748.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $748.4 million, marking a year-over-year decrease of 2225.12%. This contributed to the annual value of $872.0 million for FY2024, which is 1696.99% down from last year.
- As of Q3 2025, Intellia Therapeutics' Common Equity stood at $748.4 million, which was down 2225.12% from $715.3 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Common Equity ranged from a high of $1.2 billion in Q4 2022 and a low of $494.8 million during Q2 2021
- Its 5-year average for Common Equity is $923.8 million, with a median of $962.6 million in 2024.
- Per our database at Business Quant, Intellia Therapeutics' Common Equity soared by 23587.1% in 2021 and then tumbled by 2634.3% in 2025.
- Quarter analysis of 5 years shows Intellia Therapeutics' Common Equity stood at $1.0 billion in 2021, then increased by 18.78% to $1.2 billion in 2022, then fell by 15.01% to $1.1 billion in 2023, then decreased by 16.97% to $872.0 million in 2024, then decreased by 14.17% to $748.4 million in 2025.
- Its Common Equity stands at $748.4 million for Q3 2025, versus $715.3 million for Q2 2025 and $779.9 million for Q1 2025.